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Abstract
Objectives—Depression is an important precursor to dementia, but less is known about the role 
dementia plays in altering the course of depression. We examined whether depression prevalence, 
incidence, and severity are higher in those with dementia versus those with mild cognitive 
impairment (MCI), or normal cognition.
Design—Prospective cohort study using the longitudinal Uniform Data Set of the National 
Alzheimer's Coordinating Center (2005–2013).
Setting—34 Alzheimer Disease research centers.
Participants—27,776 subjects with dementia, MCI, or normal cognition.
Measurements—Depression status was determined by a clinical diagnosis of depression within 
the prior 2 years and by a Geriatric Depression Scale-Short Form score >5.
Results—Rates of depression were significantly higher in subjects with MCI and dementia 
compared with those with normal cognition at index visit. Controlling for demographics and 
common chronic conditions, logistic regression analysis revealed elevated depression in those 
with MCI (OR: 2.40 [95% CI: 2.25, 2.56]) or dementia (OR: 2.64 [95% CI: 2.43, 2.86]) relative to 
those with normal cognition. In the subjects without depression at the index visit (N = 18,842), 
those with MCI and dementia had higher probabilities of depression diagnosis 2 years post index 
visit than those with normal cognition: MCI = 21.7%, dementia 24.7%, normal cognition = 10.5%.
Conclusion—MCI and dementia were associated with significantly higher rates of depression in 
concurrent as well as prospective analyses. These findings suggest that efforts to effectively 
engage and treat older adults with dementia will need also to address co-occurring depression.
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The increasing number of adults over the age of 65 years in the United States is driving a 
concurrent increase in the number of individuals experiencing significant cognitive 
impairment. One of every five persons aged 65 years or older will develop Alzheimer 
disease (AD) in their lifetime, and, by 2050, the number of people with AD and other forms 
of dementia in the United States is expected to almost triple.1,2 Similarly, the likelihood of 
chronic conditions increases with age, and the number of chronic conditions is linked to 
risks of mortality, poor functional outcomes, and increased health care utilization.3–5 
Persons with multiple chronic conditions use a disproportionate number of resources—for 
example, 66% of total healthcare spending is directed toward care for the approximately 
27% of Americans with multiple chronic conditions.6
Depression is a common chronic condition in elderly patients and often accompanies other 
chronic conditions. Depression carries its own risks for mortality, higher healthcare costs, 
and disability.7–10 Though individual studies are not universally consistent, recent reviews 
demonstrate depression is a risk factor for dementia of both vascular and Alzheimer 
types.11–14 The U.S. Department of Health and Human Services’ Multiple Chronic 
Conditions Strategic Framework,15 the Centers for Disease Control and Prevention's 
Healthy Brain Initiative Roadmap,16 and the National Institutes of Health Cognitive and 
Emotional Health project17 all call for a better understanding of the impact that cognitive 
impairment has on chronic conditions. They suggest that analysis of existing data sets is one 
viable avenue for understanding the public health impact of comorbid cognitive impairment. 
This project used data from the National Alzheimer Coordinating Center (NACC) to 1) 
examine the longitudinal association of cognition status with clinician-rated depression and 
symptom self-report, controlling for demographic, contextual, and medical confounders; and 
2) examine the prospective development of depression by cognition status, using the 
subsample of patients not meeting clinician-rated depression at the index visit (and 
controlling for the same potential confounders).
METHODS
Setting
Since 2005, the NACC has maintained the Uniform Data Set (UDS) containing standardized 
clinical, cognition, and diagnostic data on all subjects in the National Institute on Aging 
Alzheimer Disease Centers. Centers acquire subjects in various ways, including referral 
from clinicians, self-referral, referrals from concerned family members, active recruitment 
through community organizations, and volunteers who wish to contribute to dementia 
research. Most centers also enroll volunteer control subjects through similar mechanisms. 
Written, informed consent is obtained from subjects or their informants. Data are collected 
from subjects and self-designated informants by trained personnel using structured, 
standardized assessment instruments including a battery of neuropsychological tests. 
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Research using the NACC database has been approved by the University of Washington 
institutional review board.
At the time of this study, the sample included 27,776 subjects from the 34 past and present 
Alzheimer Disease Centers. Fifty-seven percent were women, and the mean age at index 
visit was 73.3 years (SD: 10.5). Eighty percent of the sample identified as White, and 13.9% 
identified as Black, with 7.8% of participants reporting Hispanic descent. The database 
spans from September 2005 (start of the UDS) through March 2013 (time of the NACC data 
freeze).
Measures
Dementia diagnoses are made by a consensus team or the physician conducting the 
examination using the results of a structured clinical history and clinical dementia rating 
form.18–20 Mild cognitive impairment (MCI) classification initially required an amnestic 
component but was revised to include other cognitive domains and did not require memory 
impairment.18 Depression diagnosis within the preceding 2 years was assessed by clinician 
diagnosis from a structured clinical history based on subject/informant report, medical 
records, and/or observation. The clinical diagnosis of depression includes depressive 
disorders for which a clinician was consulted, whether or not treatment (behavioral or drug) 
was received. Depression includes major depressive disorder, situational depression, bipolar 
disorders, dysthymic disorders, and other mood disorders. Assessment can include 
Diagnostic Statistical Manual diagnoses, chart reviews, clinicians’ opinion, or whether the 
subject is taking a selective serotonin reuptake inhibitor for a depressive/mood disorder. 
Current depressive symptoms were assessed using the Geriatric Depression Scale Short 
Form (GDS-SF)21 administered at intake and annual follow-up evaluations. Antidepressant 
medication (ADM) use was obtained using a medication inventory form that recorded all 
medications taken. Specific dose and duration of use data were not available. Functional 
independence was determined with the use of a categorical variable in the standardized 
clinical assessment with response choices of: independent, needing assistance with complex 
tasks, needing assistance with basic tasks, or dependent.
Statistical Analyses
Subject characteristics were examined via descriptive statistics by cognition status (i.e., 
normal cognition, mild cognitive impairment, dementia). Differences between cognition 
groups at the index visit were assessed using one-way analysis of variance for continuous 
outcomes and χ2 tests of independence for categorical variables. Primary analyses focused 
on associations of cognition status with depression outcomes, including clinician-rated 
depression in the past 2 years and subject-reported depressive symptoms. Logistic regression 
was used for the binary outcome of clinician-rated depression, whereas negative binomial 
regression22 was used for the GDS because it is bounded at zero and strongly skewed in the 
present sample. An initial model included demographic characteristics only (age, sex, and 
education), and a second model included a variety of potential confounding variables 
(current living situation, level of independence, residence, history of heart attack, history of 
congestive heart failure, history of stroke, current hypertension, and current diabetes).
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Both of the regressions examine the cross-time association of cognition status with 
depression, controlling for potential confounders. To examine the prospective association of 
cognition status with depression, regressions examined the subsample of individuals who 
were not classified as depressed (based on clinician report) at the index visit. Although we 
considered time-to-event regression models, depression status varies over time, and hence 
similar regression models (i.e., either logit or negative binomial) to those used for previous 
analyses were used here. The primary interest in this model centered on the interaction 
between cognition status (MCI, dementia, or normal cognition) and time since index visit to 
determine whether depression was more likely to develop over time among those with MCI 
or dementia who were not depressed at the index visit. We also conducted an analysis with 
people meeting clinical criteria for depression at index to examine whether cognitive status 
(dementia, MCI, or normal cognition) predicted increased severity of depression as 
measured by GDS scores, adjusting for the same confounders as outlined above.
All regression models used cluster-adjusted standard errors to control for the within-person 
correlation due to repeated measures.23 Use of ADM and participant death were considered 
in sensitivity analyses. All tests used a two-tailed significance of p less than 0.05, and all 
analyses were done using R v3.0.1.24
RESULTS
Table 1 presents descriptive statistics on study variables at the index visit by cognition status 
at the index visit. Relative to subjects with normal cognition, those with dementia or MCI 
were more likely to be women, were somewhat older, had somewhat less educational 
attainment, and were less likely to live alone. As expected, there were strong differences 
between groups in their functional independence, with dementia patients much more likely 
to need some assistance, and virtually all normal cognition patients falling into the fully 
independent category. Patients with MCI were generally independent. On physical health 
background characteristics, differences among groups were not as dramatic, with relatively 
similar prevalence of cardiovascular disease and diabetes. Finally, at the index visit, patients 
with dementia or MCI were more than twice as likely to have a clinician-rated diagnosis of 
depression, as well as higher levels of current depressive symptomatology.
Table 2 contains results from logistic and negative binomial regressions for clinician-rated 
depression and depressive symptoms, respectively. Controlling for basic demographic 
characteristics, there is a strong association of both dementia and MCI with clinician-rated 
depression and depressive symptoms as reported by the GDS. Although the association is 
somewhat attenuated after including additional covariates, results still suggest a strong, 
contemporaneous relationship between cognition status and depression, with both dementia 
and MCI patients approximately 2.5 times more likely to have depression. We conducted an 
additional analysis of persons with a clinical diagnosis of depression at baseline only to 
examine whether cognition status is associated with increased depression severity as 
measured by the GDS. We found that, relative to normal controls, both MCI (relative risk 
[RR]: 1.34, 95% confidence interval [CI]: 1.27, 1.40) and dementia (RR: 1.14, 95% CI: 
1.08, 1.21) report significantly more depressive symptoms.
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The preceding analyses suggest a strong association between concurrent cognitive 
impairment and depression over time; however, the descriptive data in Table 1 suggested 
that dementia and MCI patients were more likely to have depression at the index visit. Thus, 
a final analysis examined a prospective association, by selecting the subset of individuals 
who did not have clinician-rated depression at the index visit (normal cognition: N = 8,352; 
dementia: N = 5,880; MCI: N = 4,610). Analysis of clinician-rated depression included all 
previous covariates and as well as interaction terms between time since index visit and 
cognition status. Because there was evidence of nonlinear trends, a quadratic term for time 
was included.
All time and cognition status × time interaction terms were significant (all p <0.001). Due to 
the interactions and nonlinear terms for time, predicted regression lines are presented in 
Figure 1 (with other covariates set to reference values). By definition, all patients in this 
subsample begin without depression, but there are fairly dramatic differences in proportion 
of patients with depression by cognition status that begin within the first year or two of 
follow-up and become more dramatic over time. At 2 years post index visit, 10% of patients 
with normal cognition are predicted to have developed depression, whereas 22% of MCI 
patients and 25% of dementia patients have developed depression. By 4 years post index 
visit, these have increased to 20% (normal cognition patients), 38% (MCI patients), and 
43% (dementia patients). A similar set of analyses focused on depression symptoms as 
measured by the GDS-SF did not reveal a similar pattern; instead, there was a notable main 
effect of higher depression symptoms in MCI and dementia relative to normal cognition, but 
depression severity did not increase over time.
Results thus far suggest a strong association over time, as well as a prospective association 
between cognition status and future depression. Two additional confounds were considered 
in sensitivity analyses, however. First, there could be differential use of ADM, where 
underprescribing of ADM to MCI and dementia patients may explain their higher depression 
rates. This does not appear to be the case, however, as dementia patients are the most likely 
to report ADM use in subpopulations rated as being depressed (MDementia = .69, MMCI = .
59, MNormal Cognition .59) and among those rated as not being depressed (MDementia = .23, 
MMCI = .10, MNormal Cognition .07). Regression analyses controlling for ADM yielded 
substantively identical conclusions to those presented earlier. Finally, the proportion of 
dementia patients who died during the study (3,082 of 10,486, 29.4%) was higher than the 
proportion for MCI (756 of 7,096, 10.7%) or normal cognition patients (740 of 10,194, 
7.3%). Regression analyses stratified by death status revealed that the association of 
depression and cognition status was very similar within patients who died during study 
follow-up and those who did not. The only notable difference was that patients with normal 
cognition who died at some point during follow-up were somewhat more likely to have 
become depressed than those normal cognition patients who did not die during follow-up 
(see Fig. 2).
DISCUSSION
The results of this large and well-characterized sample, which includes patients with normal 
cognition, MCI, and dementia, present robust evidence that cognitive impairment is 
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associated with significantly higher rates of depression. Prior research found no association 
of cognitive impairment with severe depression in a smaller sample with less–well-
characterized dementia status,25 and some work using only the Mini-Mental State Exam 
(MMSE) and GDS found increased odds of depression in those with MMSE scores below 
24.26 Although results are strongest using the clinician-rated depression variable, our finding 
is supported by significantly higher current depression on the GDS-SF. The finding of 
increased development of depression in subjects without depression at index suggests that 
the increased risk of depression in cognitively impaired subjects is not entirely due to 
continued presence of previous depression. The results of analyses of subjects with clinical 
diagnosis of depression at the index visit also suggest that the severity of depression over 
time is worse in subjects with MCI or dementia. Antidepressant use does not confound these 
results.
The results suggest that from a public health standpoint, it is important to consider 
depression not only as a predictor of dementia as established in prior research, but as a 
comorbid condition that will develop during the course of dementia—because the results 
demonstrate significantly higher rates of depression in cognitively impaired subjects who 
were not depressed at intake. Thus, community-based interventions for treatment of 
dementia will need to be prepared to address depression27 and may need to include high 
levels of collaboration between nurse managers and physicians in order to significantly 
improve depressive symtpoms.28 Zlatar and colleagues have made a similar 
recommendation around the importance of considering depression when evaluating subjects 
with subjective complaints of cognitive impairment who demonstrate normal cognitive 
testing.29 Conversely, evidence-based approaches for treatment of depression in older adults 
will need to accommodate treatment of subjects with dementia-severity cognitive 
impairment. Currently, most community- and clinic-based geriatric depression effectiveness 
trials exclude subjects with significant cognitive impairment. Also, other factors such as 
race/ethnicity, education, income, language, acculturation, and family and community 
support need to be considered when examining the recognition and treatment of depression 
in diverse elders with cognitive impairment.30
The continued association of depression and cognitive impairment after the development of 
MCI or dementia supports a possible common patho-physiological pathway of the 
conditions. Stress theory models suggest that exposure to significant stress increases 
corticotropin releasing factor and that impaired hypothalamic-pituitary-adrenal axis 
inhibitory feedback leads to elevated glucocorticoids, which are associated with smaller 
hippocampal volumes, depressive features, and dementia.31,32 Similarly, research on 
inflammation models of the illnesses find increased inflammatory markers of interleukin and 
c-reactive proteins in depression and a role for inflammatory disease processes in Alzheimer 
and vascular dementia pathophysiology.33 Heterogeneity of types of depression, combined 
with increased recognition of heterogeneity of types of Alzheimer dementia as well as other 
dementia, help explain the lack of consistent findings across studies of pathophysiology or 
treatment trials.33,34
This complicates translation of effective treatments to these disease models. Several papers 
have looked at the prevalence and/or incidence of depression in persons with cognitive 
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impairment. Lyketsos and colleagues35 examined the prevalence of depression in persons 
with dementia and with mild cognitive impairment (N = 682). Depression was defined using 
the Neuropsychiatric Inventory36 and 32% and 20% of persons with dementia or MCI, 
respectively, reported depressive symptoms. These rates are higher than our prevalence of 
depressive symptoms (as defined by the GDS-SF) of 17% and 14% for persons with 
dementia or MCI, and lower than our reported depression prevalence using a clinical 
diagnosis (43% for dementia and 35% for MCI). Our study differs from the Lyketsos paper 
as it includes a significantly larger sample (N = 27,776) of both persons with and without 
cognitive¼impairment. We also include information drawn from clinical depression 
diagnoses in addition to a depression scale instrument and are able to report rates of the 
development (incidence) of depression in those without depression at intake. Because the 
GDS scoring is responsive to change over time, we are able to analyze change in depression 
severity over time as well.
Peters37 reported prevalence of depressive symptoms data for persons with dementia; with 
cognitive impairment, no dementia (CIND); and with normal cognition using data from the 
Cache County Study (N = 5,092). Their reported prevalence of depressive symptoms was 
comparable to ours for persons with normal cognitive function (4.9% in their study versus 
5.0% for our study) and for persons with CIND/MCI (16.9% versus 14.0%), and were 
higher for persons with dementia (29.9% versus 17%). As with the Lyketsos paper, this 
study was cross-sectional and used the Neuropsychiatric Inventory and therefore was not 
able to comment on incident depression in persons with and without cognitive impairment, 
or on the change in depression severity over time. Lastly, Panza and colleagues38 conducted 
a review of studies that compared the prevalence and incidence of depression for persons 
with MCI only. Most of the reported studies were cross-sectional and/or had a small sample 
size, and, as defined by their review criteria, none of the papers included persons with 
normal cognitive function or with dementia. They found a range of prevalence rates for 
depressive symptoms (4%–69%) largely due to the inconsistencies in how depression is 
assessed and MCI is defined. Other recent papers such as Reinlieb and colleagues39 found 
elevated rates of depressive symptoms for persons with MCI as well compared with those 
without cognitive impairment. Two papers included in Panza et al.'s review38 described 
incident depression, reporting rates of 29.6/100 person-years for the one population-based 
study and 11.7/100 person years for the one hospital-based study. We conducted a post hoc 
analysis to estimate our incident rates of depression per 100 person-years and found rates of 
4.4/100 person-years for persons with normal cognition, 8.3/100 person-years for persons 
with MCI, and 11.1/100 person-years for persons with dementia, suggesting lower rates than 
the two studies described in the Panza review for persons with MCI. It should be noted that 
our definition of depression/depressive symptoms and our control group are different than 
those reported in the review by Panza and colleagues.
There are several limitations to this study. Although the GDS-SF is a valid, established, 
screening instrument, it is not a diagnostic instrument and so the GDSSF findings here 
should not be interpreted as specific to major depression. We do, however, include 
information about depression as defined by a clinical diagnosis as well and indicate where 
the data are consistent and where they differ. The clinical diagnosis was made using a 
standardized comprehensive history that included other items that may contribute to 
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depressive symptoms, such as past history of bipolar disorder; medications such as beta-
blockers for congestive heart failure or hypertension; and anemia, hypothyroidism, or other 
medical illnesses. In addition, we adjusted for many of these possible cofounders in our 
analysis. Dosages and durations of ADM were not available in the UDS and so it is 
uncertain whether differences in the adequacy of treatment contributed to increased rates of 
depression in patients with cognitive impairment. Further research is warranted to study the 
impact of appropriately prescribed and managed ADM in persons with and without 
cognitive impairment.
Despite these limitations, these results consistently show increased rates of depression in 
patients with dementia and mild cognitive impairment at cross-sectional intake evaluations 
and over longitudinal follow-ups, including analysis of incident depression. The results 
suggest that beyond being a predictor or prodromal condition, depression is an important 
comorbid chronic condition in patients with dementia and mild cognitive impairment.
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Predicted depression diagnosis over time.
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Predicted depression diagnosis over time, by mortality.
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TABLE 1
Baseline Characteristics of the NACC Sample (N = 27,776)
N (%) of Participants
Normal Cognition N = 10,194 Dementia N = 10,486 MCI N = 7,096 χ2; df; p Value
Age, y 72.4 75.7 74.3 433.46; 2; p <0.001
Women 6,654 (65) 5,533 (53) 3,691 (52) F = 136.74; 2,2773; p <0.001
Race 131.6; 4; p < 0.001
    White 8,292 (81) 8,622 (82) 5,526 (78)
    Black 1,511 (15) 1,237 (12) 1,110 (16)
    Other 386 (4) 619 (6) 449 (6)
Hispanic 613 (6) 919 (9) 625 (9) 69.3; 2; p <0.001
Education 825.5; 8; p <0.001
    Less than HS 504 (5) 1,449 (14) 702 (10)
    HS graduate 3,582 (35) 4,384 (42) 2,715 (38)
    Bachelors 2,655 (26) 2,307 (22) 1,693 (24)
    Masters 2,394 (24) 1,429 (14) 1,285 (18)
    Doctorate 1,002 (10) 807 (8) 671 (9)
Not live alone 6,766 (66) 9,039 (86) 5,162 (73) 1,136.92; 2; p <0.001
Function 1,4847.09; 8; p <0.001
    Independent 9,848 (97) 1,929 (18) 5,460 (77)
    Help w/complex activities 241 (2) 4,706 (45) 1,391 (20)
    Help w/basic activities 83 (1) 2,566 (24) 192 (3)
    Dependent 10 (0) 1,213 (12) 25 (0)
Depression
    GDS-SF > 5 524 (5) 1,455 (17) 981 (14) 628.38; 2; p <0.001
    Clinician-rated diagnosis 1,801 (18) 4,474 (43) 2,430 (35) 1,575.98; 2; p <0.001
Heart attack/cardiac arrest 34.68; 4; p <0.001
    None 9,650 (95) 9,748 (93) 6,593 (93)
    Recent 95 (1) 119 (1) 72 (1)
    Remote 415 (4) 572 (5) 411 (6)
CHF 16.37; 4; p = 0.003
    None 9934 (98) 10,125 (97) 6,880 (97)
    Recent 179 (2) 229 (2) 150 (2)
    Remote 56 (1) 99 (1) 54 (1)
Stroke 171.62; 4; p <0.001
    None 9,878 (97) 9,701 (93) 6,658 (94)
    Recent 78 (1) 185 (2) 96 (1)
    Remote 218 (2) 527 (5) 305 (4)
Hypertension 115.46; 4; p <0.001
    None 5,075 (50) 4,998 (48) 3,062 (43)
    Recent 4,825 (48) 5,013 (48) 3,768 (53)
    Remote 257 (3) 439 (4) 235 (3)
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N (%) of Participants
Normal Cognition N = 10,194 Dementia N = 10,486 MCI N = 7,096 χ2; df; p Value
Diabetes 75.32; 4; p <0.001
    None 8,984 (88) 9,108 (87) 5,952 (84)
    Recent 1,135 (11) 1,255 (12) 1,054 (15)
    Remote 40 (0) 80 (1) 61 (1)
Notes: MCI: mild cognitive impairment; df: degrees of freedom; HS: high school; w/: with; GDS-SF: Geriatric Depression Scale-Short Form; 
CHF: congestive heart failure.
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TABLE 2
Regressions for Clinician-Rated Depression and Depressive Symptoms
Model with Demographics Model with All Covariates
Dementia MCI Dementia MCI
Depression diagnosis
a
 OR (95% CI)
4.10 (3.85-4.37) 2.69 (2.52-2.87) 2.64 (2.43-2.86) 2.40 (2.25-2.56)
Depressive symptoms
b
 RR (95% CI)
1.95 (1.88-2.01) 1.81 (1.76-1.88) 1.60 (1.53-1.68) 1.71 (1.65-1.77)
Notes: MCI: mild cognitive impairment; OR: Odds Ratio; CI: confidence interval; RR: Relative Risk.
a
Clinician-rated depression was defined by a standardized assessment of a clinical diagnosis of depression within the prior 2 years.
b
Depressive symptoms were defined by a Geriatric Depression Scale-Short Form score greater than 5.
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